Evaluating the Effectiveness of Ziresovir AK0529 Compared to Placebo in Treating High-Risk Adults with Respiratory Syncytial Virus Infection in a Randomized, Double-Blind Study

What this Trial Is About

Respiratory syncytial virus RSV is a major cause of lower respiratory tract infections in infants, the elderly, and people with weakened immune systems. It can lead to serious complications like bronchiolitis, pneumonia, and affect other organs, increasing hospitalizations and death risks, especially in high-risk adults. This study evaluates the effectiveness of Ziresovir AK0529 compared to a placebo in treating RSV by measuring how quickly symptoms of RSV-related lower respiratory tract disease resolve. Participants will be randomly assigned to receive either 200 mg or 300 mg of Ziresovir twice daily, or a matching placebo, all administered orally as enteric capsules for 5 days. This double-blind study compares these treatments to assess the time it takes for respiratory symptoms to improve, with treatment starting within 5 days of symptom onset. The study is conducted in a parallel design to evaluate the outcomes effectively. During the study, participants will be monitored up to 27 days to track symptom resolution and viral load changes. Researchers will assess respiratory and systemic symptoms at multiple time points, including days 3, 6, 13, and 27. Safety is monitored by recording any adverse events throughout the study. The total participation duration covers treatment and follow-up visits to evaluate both symptom improvement and drug plasma levels.

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.